. A CRISPR/Cas9 based strategy to manipulate the Alzheimer's amyloid pathway. bioRχiv 310193; Apri 28, 2018


Please login to recommend the paper.


  1. I think the György et al. paper is quite exciting. They clearly show that they can target specifically the mutant allele in fibroblasts and that these express lower amounts of Aβ40 and Aβ42. So the in vitro part is quite convincing. The in vivo part is not so clear, since they state that it is difficult for them to measure delivery of the CRISPR constructs by the AAV virus. It would be interesting to see more systematic analyses of the targeted cells in the hippocampus. How far can the virus spread and alter the mutant allele?

    They also claim that it was advantageous to target the Swedish APP mutation since it is a mutation affecting two nucleotides. This keeps me wondering how effective the approach is when only a single nucleotide is affected. I also did not see any off-target screening in the paper and I was wondering if that was addressed. Obviously this is a concern, even though the latest research has shown that there are few, if any, off-target effects it would have been important to check. Also, one needs to keep in mind that AD is rarely caused by such familial mutations, but for the few affected individuals this could be an appropriate therapy. 

    View all comments by Kristine Freude

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. In Mice, CRISPR-Based Alzheimer’s Therapies Inch Forward